IDH1
Isocitrate dehydrogenase [NADP] cytoplasmic
As of the edition of 20 October 2026, IDH1 (isocitrate dehydrogenase [NADP] cytoplasmic, UniProt O75874) has 6 drugs tested at it and 7 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O75874
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 64
- Disease areas
- Cancer; Blood and lymph; Digestive system; Immune system; Inherited and neonatal; Lungs and airways; Nervous system; Pregnancy and women's health
- Registered trials of its drugs
- 113
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 1 |
| Stopped | 1 |
| Status not established | 1 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ivosidenib | Marketed | Phase 3 | Ends 2033 |
| Vorasidenib | Marketed | Phase 3 | Ends 2039 |
| Olutasidenib | Marketed | Phase 4 | Ends 2039 |
| Safusidenib | Active | Phase 3 | none listed |
| IDH305 | Stopped | Phase 2 | none listed |
| BAY1436032 | Status not established | Phase 1 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Engaged | 4 |
| Undetermined | 1 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| Novartis | Route A |
| Rigel Pharmaceuticals | Route B |
The other 5 companies at IDH1
In the product7 companies in all; 5 are not named here, and no score is.
See the 7 companies at IDH1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.